Skip to main content

Table 3 Inhaled corticosteroid usage

From: The adherence to and utility of the Global Initiative for Chronic Obstructive Lung Disease guidelines for treating COPD among pulmonary specialists: a retrospective analysis

Inhaled Corticosteroid Usage

 

Group A

Group B

Group C

Group D

ICS + LABA + LAMA

30.60%

47.77%

30.77%

63.33%

ICS + LABA

24.20%

17.92%

15.38%

15.71%

ICS only

1.42%

1.19%

3.85%

0.48%

ICS + LAMA

0.00%

0.43%

0.00%

0.00%

Total

56.23%

67.32%

50.00%

79.52%

  1. LAMA long-acting muscarinic antagonist, LABA long-acting beta agonist, ICS inhaled corticosteroid